Syncom Formulation (India) Share Price

Name: Syncom Formulation (India)
Brand: Syncom Formulation (India)

Small Cap

₹24.73

-0.86 (-3.36%)

16 September, 2024 11:39 BSE: 524470 NSE: SYNCOMF ISIN: INE312C01025

Start SIP in Syncom Formulation (India)

Start SIP

Syncom Formulation (India) Performance

Day Range

Low 25
High 26

₹ 24

52 Week Range

Low 7
High 28

₹ 24

Open Price26
Previous Close26
Volume7789884

Syncom Formulation (India) Chart

Over 1 Month + 57.65%
Over 3 Month + 96.5%
Over 6 Month + 102.46%
Over 1 Year + 186.44%

Syncom Formulation (India) Key Statistics

P/E Ratio	81.4
PEG Ratio	2.1
Market Cap Cr
Price to Book Ratio	8.1
EPS	0.3
Dividend	0
Relative Strength Index	68.82
Money Flow Index	79.78
MACD Signal	2.07
Average True Range	1.86

Syncom Formulation (India) Investment Rating

Master Rating:
Syncom Formulations India has an operating revenue of Rs. 290.81 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 45% and 75% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Syncom Formulation (India) Financials

Standalone Consolidated

Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios
Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios

Indicator	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Oper Rev Qtr Cr	87	73	63	62	59	61
Operating Expenses Qtr Cr	76	64	57	56	53	55
Operating Profit Qtr Cr	10	9	7	6	6	6
Depreciation Qtr Cr	1	1	1	1	1	1
Interest Qtr Cr	0	1	1	1	1	1
Tax Qtr Cr	2	2	2	2	2	2
Net Profit Qtr Cr	8	7	6	6	4	8

Indicator	Mar 2024	Mar 2023
Total Revenue Annual Cr	271	239
Operating Expenses Annual Cr	231	205
Operating Profit Annual in Cr	28	20
Depreciation Cr	5	5
Interest Annual Cr	4	3
Tax Annual Cr	8	6
Net Profit Annual Cr	24	20

Indicator	Mar 2024	Mar 2023
Cash from Operating Activity Annual Cr	-6	10
Cash from Investing Activity Annual Cr	84	-45
Cash from Financing Annual Activity Cr	-15	35
Net Cash Flow Annual Cr	63	1

Indicator	Mar 2024	Mar 2023
Total ShareHolders Funds Annual Cr	286	256
Fixed Assets Annual Cr	120	116
Total Non Current Assets Annual Cr	129	196
Total Current Assets Annual Cr	263	181
Total Assets Annual Cr	392	377

Indicator	Mar 2024	Mar 2023
Book Value Per Share Annual Rs	3	3
ROE Annual %	8	8
ROCE Annual %	12	11
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	16	15

Indicator	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Oper Rev Qtr Cr	87	75	65	64	60	61
Operating Expenses Qtr Cr	77	65	58	57	53	55
Operating Profit Qtr Cr	10	9	7	6	6	6
Depreciation Qtr Cr	1	1	1	1	1	1
Interest Qtr Cr	0	1	1	1	1	1
Tax Qtr Cr	2	3	2	2	2	2
Net Profit Qtr Cr	8	7	7	7	4	8

Indicator	Mar 2024	Mar 2023
Total Revenue Annual Cr	277	239
Operating Expenses Annual Cr	234	205
Operating Profit Annual in Cr	30	20
Depreciation Cr	5	5
Interest Annual Cr	4	3
Tax Annual Cr	9	7
Net Profit Annual Cr	25	20

Indicator	Mar 2024	Mar 2023
Cash from Operating Activity Annual Cr	-6	11
Cash from Investing Activity Annual Cr	83	-45
Cash from Financing Annual Activity Cr	-15	35
Net Cash Flow Annual Cr	63	1

Indicator	Mar 2024	Mar 2023
Total ShareHolders Funds Annual Cr	288	256
Fixed Assets Annual Cr	120	69
Total Non Current Assets Annual Cr	130	196
Total Current Assets Annual Cr	275	182
Total Assets Annual Cr	405	378

Indicator	Mar 2024	Mar 2023
Book Value Per Share Annual Rs	3	3
ROE Annual %	9	8
ROCE Annual %	13	11
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	16	15

Invest in Syncom Formulation (India)

Syncom Formulation (India) Technicals

EMA & SMA

Current Price

₹24.73

-0.86 (-3.36%)

Bullish Moving Average
___
0

Bearish Moving Average
___
0

EMA SMA

20 Day
₹21.93

50 Day
₹18.67

100 Day
₹16.48

200 Day
₹14.52

20 Day
₹21.43

50 Day
₹17.58

100 Day
₹15.25

200 Day
₹14.56

Syncom Formulation (India) Resistance and Support

PIVOT

₹25.93

Resistance
First Resistance	26.45
Second Resistance	27.30
Third Resistance	27.83

RSI	68.82
MFI	79.78
MACD Single Line	2.07
MACD	2.47

Support
First Support	25.07
Second Support	24.54
Third Supoort	23.69

Syncom Formulation (India) Delivery and Volume

Period	NSE + BSE Volume Avg	NSE + BSE Delivery Volume Avg	NSE + BSE Delivery Volume %
Day	13,181,676	608,466,164	46.16
Week	37,931,270	1,252,111,216	33.01
1 Month	30,873,049	1,072,529,709	34.74
6 Month	9,282,615	409,363,314	44.1

Syncom Formulation (India) Result Highlights

Syncom Formulation (India) Synopsis

NSE-Medical-Diversified

Syncom Formul. is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 224.64 Cr. and Equity Capital is Rs. 94.00 Cr. for the Year ended 31/03/2023. Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759.

Market Cap	2,406
Sales	286
Shares in Float	46.06
No of funds	4
Yield	1.01

Book Value	8.39
U/D Vol ratio	2.2
LTDebt / Equity
Alpha	0.4
Beta	0.94

Syncom Formulation (India) Shareholding Pattern

Owner Name	Jun-24	Mar-24	Dec-23	Sep-23
Promoters	50.57%	50.57%	50.57%	50.57%
Mutual Funds
Foreign Portfolio Investors	0.09%	0.08%
Individual Investors	45.07%	44.85%	44.82%	44.76%
Others	4.27%	4.5%	4.61%	4.67%

Syncom Formulation (India) Management

Name	Designation
Mr. Kedarmal Shankarlal Bankda	Exe.Chairman & W T D
Mr. Vijay Shankarlal Bankda	Managing Director
Mrs. Rinki Ankit Bankda	Whole Time Director
Mr. Krishna Das Neema	Independent Director
Mr. Praveen Jindal	Independent Director
Mr. Vinod Kumar Kabra	Independent Director
Mrs. Ruchi Jindal	Independent Woman Director
Mr. Ritesh Kumar Lunkad	Addnl.Independent Director
Mr. Ankit Jain	Addnl.Independent Director

Syncom Formulation (India) Forecast

Price Estimates

2,000(9.8%)

1,758(-3.5%)

1,590(-12.7%)

Other Analyst Rating

Syncom Formulation (India) Corporate Action

Board

Date	Purpose	Remarks
2024-08-12	Quarterly Results
2024-05-17	Audited Results
2024-02-14	Quarterly Results
2023-11-08	Quarterly Results
2023-08-14	Quarterly Results

Syncom Formulation (India) MF Shareholding

Name	Amount(cr)

Syncom Formulation (India) FAQs

What is Share Price of Syncom Formulation (India) ?

Syncom Formulation (India) share price is ₹24 As on 16 September, 2024 | 11:25

What is the Market Cap of Syncom Formulation (India) ?

The Market Cap of Syncom Formulation (India) is ₹2324.6 Cr As on 16 September, 2024 | 11:25

What is the P/E ratio of Syncom Formulation (India) ?

The P/E ratio of Syncom Formulation (India) is 81.4 As on 16 September, 2024 | 11:25

What is the PB ratio of Syncom Formulation (India) ?

The PB ratio of Syncom Formulation (India) is 8.1 As on 16 September, 2024 | 11:25

Syncom Formulation (India) Key Statistics

P/E Ratio	81.4
PEG Ratio	2.1
Market Cap Cr
Price to Book Ratio	8.1
EPS	0.3
Dividend	0
Relative Strength Index	68.82
Money Flow Index	79.78
MACD Signal	2.07
Average True Range	1.86

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91